分类: 未分类

  • 英国新冠疫情解封四阶段计划

    英国在周一(2月22日)晚间宣布四阶段逐步“解封”计划,希望最快在今年6月21日之前能完全解除防疫措施,但这四阶段都须在满足相关的条件下逐步推进。

    英国解封四阶段

    • 第一阶段

    从3月8日开始,英格兰地区所有学校全数开放,并允许进行课后户外运动和活动。容许两人在室外公共场所(例如公园)休闲娱乐,这意味着他们可以坐下来喝饮料或野餐。

    3月29日开始,允许两个家庭混合或最多六人在户外聚会。这包括在私人花园中聚会。网球或篮球场等户外运动设施重新开放,成人和儿童运动(如板球)都将恢复。

    中学生能参加考试,并被要求在教室和走廊等空间内戴口罩。

    每个解封阶段至少要有五周间隔,以​​便评估每阶段中的新冠感染率和住院人数之变化。

    • 第二阶段

    从4月12日开始,将重新开放与经济行为等有关的场所,包含:

    • 开放贩售非生活必需品的零售商店、理发馆和图书馆等公共场所。
    • 开放户外空间,例如外卖酒精的店铺、啤酒花园、动物园和主题公园。
    • 室内休闲设施开放,如游泳池和健身房。
    • 自给自足的度假住宿地,例如自炊式农舍和露营地。

    但是一些社交活动仍继续禁止。这意味着不同家庭,不得在“室内”混合聚会。

    约翰逊并确认,英格兰晚上的宵禁将会解除,包含可以在外用餐与饮酒,以拯救伦敦陷入困境的酒店业。他又说,针对目前非商务国际旅行限制的审查结果,最早将在4月12日宣布。

    英国境内开放旅游(同一住户可以过夜)。此外,葬礼最多可容纳30人,婚礼最多可容纳15位客人。


    • 第三阶段

    第三阶段解封将从5月17日开始(前提是之前的数据显示出可行),将取消户外聚会“六人限制”,并放宽至30人。

    • 允许两个家庭或六人可以在室内混合聚会,并在户外招待场所(如酒吧)中聚会,并检视户外六人聚会限制是否取消。
    • 电影院、博物馆、旅馆、表演和体育竞赛开放。社交距离仍需继续施行,在此规定下,在一些大型的足球场或户外场馆中,做多可达1万名观众观赏比赛。
    • 最多可容纳30人参加婚礼、招待会、葬礼和守灵。

    约翰逊又称,这一步骤还将“考虑新冠疫情身份认证”(称为疫苗注射的护照),用以帮助室内场所可以安全地重新开放。

    在进入第四阶段前,英国官员将审核是否继续维持社交距离和其它旨在减少病毒传播的“长期措施”,这包括“一米多”的社交距离规则和戴口罩规定。政府还将考虑是否取消“在家工作”的指南,政府称民众该继续遵循防疫规定,直到对这些政策的审查完成。

    • 第四阶段

    从6月21日开始,政府可能会取消所有关于社交距离及接触的限制,并重新开放最后一批商业活动空间,例如夜总会(clubs)。

    政府希望从当日起能取消对婚礼和葬礼的人数限制。

    举办音乐活动的业者呼吁政府为该领域提供更多的资金支持。一个经营现场音乐表演活动的经营者向BBC说,一旦取消防疫限制,他的行业“将重新开放”。

    英国议员将在三月下旬对这四阶段的解封计划进行投票。

    防疫解封四要件:

    • 疫苗大规模接种持续;
    • 疫苗有效降低住院和死亡率;
    • 感染率不会造成住院率再次攀高;
    • 变种病毒不会改变风险评估。
  • What pregnant, breastfeeding people should know about COVID-19 vaccines

    As the COVID-19 vaccine becomes more widely available to people younger than 65 and outside of the health care community, it is raising questions for breastfeeding and pregnant people who must decide if the vaccine is right for them.

    Pfizer and BioNTech became the first vaccine maker to evaluate their COVID-19 vaccine in pregnant women when they announced a new trial Thursday.

    Their vaccine, along with Moderna’s, are the two mRNA vaccines currently available in the United States after being granted Emergency Use Authorization by the Food and Drug Administration.

    Moderna has not yet publicly released a timeline for including pregnant people in clinical trials.

    Here are six things pregnant and breastfeeding people should consider to make an informed decision about the COVID-19 vaccine.

    1. What is the science behind the COVID-19 vaccine?

    Both the Pfizer and Moderna vaccines use mRNA technology, which does not enter the nucleus of the cells and doesn’t alter the human DNA. Instead, it sends a genetic instruction manual that prompts cells to create proteins that look like the virus a way for the body to learn and develop defenses against future infection.

    They are the first mRNA vaccines, which are theoretically safer during pregnancy, because they do not contain a live virus.

    2. What are health groups saying about the COVID-19 vaccine?

    The World Health Organization (WHO) recently updated its guidance to say pregnant people at high risk of exposure to COVID-19 and those at risk of severe disease should be vaccinated.

    “While pregnancy puts women at higher risk of severe COVID-19, very little data are available to assess vaccine safety in pregnancy,” WHO said in a statement. “Nevertheless, based on what we know about this kind of vaccine, we don’t have any specific reason to believe there will be specific risks that would outweigh the benefits of vaccination for pregnant women. For this reason, those pregnant women at high risk of exposure to SARS-CoV-2 (e.g. health workers) or who have comorbidities which add to their risk of severe disease, may be vaccinated in consultation with their health care provider.”

    The CDC says people who are pregnant and breastfeeding “may choose to be vaccinated” and should talk with their health care provider, noting that breastfeeding is an important consideration but “is rarely a safety concern with vaccines.”

    The American College of Obstetricians and Gynecologists (ACOG), a professional membership organization for OB-GYNs, says both pregnant and breastfeeding people should have access to the vaccine when they are eligible for it, according the criteria of the CDC’s Advisory Committee on Immunization Practices (ACIP).

    Likewise, the Society for Maternal-Fetal Medicine (SMFM) recommends pregnant people have access to vaccines and says pregnant people should “engage in shared decision-making” about the vaccine with their doctors.

    “In general, SMFM strongly recommends that pregnant women have access to COVID-19 vaccines in all phases of future vaccine campaigns, and that she and her health care professional engage in shared decision-making regarding her receipt of the vaccine. … mRNA vaccines, which are likely to be the first vaccines available, do not contain a live virus but rather induce humoral and cellular immune response through the use of viral mRNA,” the society said in its statement. “Health care professionals should also counsel their patients that the theoretical risk of fetal harm from mRNA vaccines is very low.”

    3. What will clinical trials be like for pregnant people?

    Pfizer’s phase 2/3 trial will enroll approximately 4,000 women within weeks 24-34 of their pregnancy, the company announced in a press release.

    Half will get the vaccine, and half will get a placebo.

    The study will include healthy, pregnant woman age 18 and older in the U.S., Canada, Argentina, Brazil, Chile, Mozambique, South Africa, the United Kingdom and Spain.

    Participants in the vaccine group will receive two doses at 21 days apart — and each woman will be followed for at least 7-10 months in order to continuously assess for safety in both participants and their infants.

    Infants will also be assessed, up until 6 months of age, for transfer of protective antibodies from their vaccinated mother.

    Women enrolled in the trial will be made aware of their vaccine status shortly after giving birth to allow those women who originally received placebo to be vaccinated while staying in the study.

    4. Why weren’t pregnant people included in early clinical trials?

    Not recruiting parents-to-be in clinical trials and medical research is nothing new, according to Dr. Ruth Faden, the founder of the Johns Hopkins Berman Institute of Bioethics and a bioethicist who studies the ethics of pregnancy and vaccines.

    “For a very long time, pregnant women were not included in biomedical research evaluation efforts or clinical trials, both for concerns about fetal development and what would be the implications of giving a pregnant women an experimental drug or vaccine and also for legal liability worries from manufacturers and pharmaceutical companies,” Faden told “GMA” last month. “There’s a huge gap between what we know about the safety and effectiveness of a new drug or a new vaccine for the rest of the population and what we know about it specific to pregnancy.”

    In the case of the COVID-19 vaccines, health experts have only one of the three sources of evidence that are used to evaluate safety and efficacy during pregnancy: the data on non-pregnant people who were enrolled in the clinical trials, according to Faden.

    From that, Faden said, health experts can try to glean what side effects may happen to people who are pregnant, but it is not an exact science.

    However, it’s considered typical — and many argue ethically appropriate — to study an unknown substance first in healthy adults and then progressively in broader and broader populations. Pregnant people and children are often tested later down the line because of concerns about potential long-term harm.

    Meanwhile, while ongoing COVID-19 vaccine clinical studies don’t include pregnant people directly, some of the volunteers who sign up may become pregnant during the trial, which will give researchers some insights about the vaccine’s safety among this group.

    Former commissioner of the U.S. Food and Drug Administration (FDA), Dr. Stephen Hahn, told ABC News in December that the agency planned to look at that data.

    “In the clinical trials, we did not require a pregnancy test for entry into the clinical trials, which means that when we look at the data, there are likely going to be women of childbearing age who have gotten pregnant,” then-commissioner Hahn told ABC News chief medical correspondent Dr. Jennifer Ashton in an interview on ABC News’ Instagram Live. “So we are likely to be able to see data. I can’t prejudge those data, but it’s one of the things we’ll have to look at.”

    “Will that be enough data for us to have confidence and say pregnant women should be vaccinated? I think that’s something that we’ll have to take a look at,” he added.

    5. What risk factors should pregnant people consider?

    The question of whether an expecting parent should receive a COVID-19 vaccine will eventually come down to a number of factors, including everything from the trimester, risk factors for COVID-19, ability to remain socially distanced in their lifestyle and occupation, guidance from federal and state officials and recommendations from a person’s own physicians, experts say.

    Similar to the flu vaccine, which was not tested on pregnant people in clinical trials, health experts will need to rely on continuously incoming data to make decisions around how safe the COVID-19 vaccines are during pregnancy.

    Officials are doing the same for the general population, considering the speed at which the COVID-19 vaccines were developed, according to Faden, who noted that people who are pregnant should not be “unnecessarily alarmed.”

    “Vaccines are coming, and they’re coming before we have all of the information that we would like to have to make recommendations for pregnant people,” she said. “But this is the context in which decisions are being made and recommendations are being made for the general population, without all of the evidence we would like to have, which is why the studies will continue.”

    6. Is COVID-19 more dangerous for pregnant people?

    Even now, nearly one year into the coronavirus pandemic in the U.S., many questions remain about how pregnant people are impacted by COVID-19.

    The CDC has shared data showing that pregnant people infected with COVID-19 are at an increased risk for “intensive care unit admission, invasive ventilation, extracorporeal membrane oxygenation, and death,” compared to nonpregnant people.

    Health experts say that with or without the vaccine, pregnant people need to continue to remain on high alert when it comes to COVID-19 by following safety protocols, including face mask wearing, social distancing and hand washing.

  • Pfizer launches COVID-19 vaccine trial in pregnant women.Pfizer’s trial will include 4,000 pregnant women

    Pfizer and BioNTech have announced a new trial to evaluate their COVID-19 vaccine in pregnant women.

    Their vaccine, along with Moderna’s, are the two mRNA vaccines currently available in the United States after being granted Emergency Use Authorization by the Food and Drug Administration.

    Pregnant women were excluded from the first clinical trials, meaning there’s limited data in this group. The Centers for Disease Control and Prevention says getting vaccinated is a personal choice for anyone who is pregnant, and recommends people speak to their health care providers if they have questions about relative risks.

    Dr. Anna Durbin, professor of international health at Johns Hopkins Bloomberg School of Public Health, told ABC News, “These trials will provide important data on the safety and immunogenicity of the vaccines in pregnant women. These data weren’t collected during the Phase 3 trial and will build confidence for the use of these vaccines in women who are pregnant.”

    Moreover, while data is preliminary, studies show “the risks of COVID during pregnancy are of increased premature labor, increased intubation, and increased deaths compared to those women that don’t have COVID in pregnancy,” Dr. Jacques Moritz, medical director of TIA Women Health, told ABC News.

    Pfizer’s trial will help offer more conclusive data about the vaccine’s safety and effectiveness in pregnant women.

    “It is awesome that they are doing a clinical trial in pregnant women because the physiology is so different in pregnant women,” said Dr. Laura Riley, OB/GYN-in-Chief at NewYork-Presbyterian and Weill Cornell Medicine.

    “These data will reveal information about safety, help us to understand the side effect profile of these vaccines in this population, and the immune responses of both mother and baby,” Riley said.

    The phase 2/3 trial will enroll approximately 4,000 women within weeks 24-34 of their pregnancy, Pfizer announced in a press release.

    Half will get the vaccine, and half will get a placebo

    The study will include healthy, pregnant woman age 18 and older in the U.S., Canada, Argentina, Brazil, Chile, Mozambique, South Africa, the United Kingdom and Spain.

    Participants in the vaccine group will receive two doses at 21 days apart — and each woman will be followed for at least 7-10 months in order to continuously assess for safety in both participants and their infants.

    Infants will also be assessed, up until 6 months of age, for transfer of protective antibodies from their vaccinated mother.

    Women enrolled in the trial will be made aware of their vaccine status shortly after giving birth to allow those women who originally received placebo to be vaccinated while staying in the study.

    “Pregnant women have an increased risk of complications and developing severe COVID-19, which is why it is critical that we develop a vaccine that is safe and effective for this population,” Dr. William Gruber, senior vice president of Vaccine Clinical Research and Development for Pfizer, stated in the release.

  • Pregnant women with COVID-19 not more likely to die, but possibly more likely to get sick, studies find.The CDC tracked more than 8,200 pregnant woman who had the coronavirus

    When it comes to COVID-19 and pregnancy, there is a lot we don’t know. Now, a new report from the Centers for Disease Control (CDC) and a recent multi-center study on pregnant women with COVID-19 have provided a little bit more clarity.

    Until recently, the effects of COVID-19 on pregnant women and birth results were a mystery because there just weren’t many large studies on the topic. Pregnancy causes changes to the immune and respiratory systems, which has led to speculation that pregnant women might be more vulnerable to the disease.

    Over the course of about six months, the CDC received more than 325,000 reports of women age 15 to 44 who had tested positive for SARS-CoV-2, the virus that causes COVID-19. Of those, more than 8,200 were pregnant.

    When the CDC looked at how well these women did, they found good news and bad news. The good news is that pregnant women don’t seem any more likely to die of COVID-19 than other groups. The bad news is that they do appear to be more likely to become extremely sick, and even become hospitalized, once they get infected.

    Specifically, pregnant women were 5.4 times more likely to be hospitalized, 1.5 times more likely to be admitted to the ICU and 1.7 times more likely to be put on a ventilator. However, the CDC said that these results should be interpreted cautiously, because it’s possible that some of these women were hospitalized due to issues related to their pregnancies and not necessarily COVID-19.

    Despite worse symptoms seen in pregnant women with COVID-19, there was no difference in the risk of death between pregnant and nonpregnant women with COVID-19. Deaths occurred in 0.2% of both groups.

    This finding roughly matches that of a recent peer-reviewed study published in the Obstetrics & Gynecology journal, which also reported similar news regarding COVID-19 pregnancy mortality rates.

    Researchers at five New York City medical centers tracked more than 240 pregnant women in their third trimester with lab-confirmed COVID-19 infection. Upon admission to the hospital, around 60% of the women did not have any COVID-19 symptoms. The majority of this group remained asymptomatic throughout their delivery, with smaller numbers progressing to mild or severe COVID-19 symptoms, and one woman becoming critically ill.

    There were no deaths, a positive yet unexpected result given the increased pregnancy death rates with other coronaviruses such as SARS and Middle Eastern respiratory syndrome (MERS).

    “Our findings corroborate observational data that SARS-CoV-2 infection is associated with far less morbidity and mortality in pregnancy when compared to previous coronavirus epidemics, SARS-CoV-1 and MERS,” said Dr. Rasha Khoury, M.D., M.P.H., a obstetrics & gynecology and women’s health physician at Montefiore Health System and Albert Einstein College of Medicine.

    However, a percentage of women in the study did experience serious symptoms. A little over a quarter had mild symptoms, 26% had severe COVID-19, and 5% were critically ill. Less than 10% were admitted to the ICU and nine were intubated. This includes one critically ill woman who suffered a heart attack due to respiratory failure caused by COVID-19 pneumonia.

    Given the possibility that pregnant women might experience some of these severe problems, hospitals need to be prepared with adequate beds, ventilators and critical care providers, as patients, even those initially who are asymptomatic, can quickly progress to severe and critical symptoms, experts say.

    “It is important to recognize the critical role of close observation regardless of initial lack of symptoms,” Khoury said.

    New York researchers also discovered an interesting trend in the rate of cesarean or c-section births. Across the country, overall about a quarter of women deliver through c-section. However, among the small group of women with COVID-19 who were studied in New York, a staggering 40% ended up giving birth via c-section.

    The more severe her COVID-19 symptoms, the more likely a woman was to have a c-section. The same trend was seen with respect to preterm birth, defined as birth before 37 weeks. The more severe the COVID-19 symptoms, the higher the likelihood of preterm birth. Nevertheless, Khoury said, “nearly all neonates were unaffected, with uniformly good outcomes.”

    Obesity, defined as a BMI over 30, was the only condition associated with worse COVID-19 symptoms in Khoury’s study. Age, race-ethnicity, insurance type or other underlying medical conditions were not associated with increased COVID-19 severity. However, that stands in contrast to data from the CDC which found that Hispanic and Black pregnant women might be disproportionately affected by SARS-CoV-2 infection during pregnancy.

    Overall, there is a silver lining in these studies on pregnant women with COVID-19. Khoury notes that given asymptomatic spread, we still do not know the true prevalence of COVID-19, but he suggests that “the case fatality rate outside of pregnancy among women of reproductive age is likely as low as it is among pregnant women.”

    This is also borne out in the CDC data indicating that COVID-19 doesn’t appear to be any more deadly in pregnant women than in nonpregnant women.

    Nevertheless, additional studies investigating COVID-19 and pregnancy are needed.

    “In a city and country where maternal and infant morbidity and mortality are disproportionately higher among communities of color, it is vital that we document and attempt to address the root causes of the disproportionate burden of SARS-CoV-2 infection and COVID-19 on these same communities,” Khoury said.